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Abstract  
Type 2 diabetes mellitus has been known to increase systemic oxidative stress by chronic 
hyperglycemia and visceral obesity and aggravate cerebral ischemic injury. On the basis of our 
previous study regarding a water-soluble extract from the culture medium of Ganoderma lucidum 
mycelia (designed as MAK), which exerts antioxidative and neuroprotective effects, the present 
study was conducted to evaluate the preventive effects of MAK on apoptosis and necroptosis, a 
programmed necrosis induced by hypoxia/ischemia (H/I) in type 2 diabetic KKAy mice. H/I was 
induced by a combination of unilateral common carotid artery ligation with hypoxia (8% O2 for 20 
min) and subsequent reoxygenation. Pretreatment with MAK (1 g/kg, p.o.) for a week significantly 
reduced H/I-induced neurological deficits and brain infarction volume assessed at 24 h of 
reoxygenation. Histochemical analysis showed that MAK significantly suppressed superoxide 
production, neuronal cell death, and vacuolation in the ischemic penumbra, which was accompanied 
by a decrease in the numbers of TUNEL- or cleaved caspase-3-positive cells. Furthermore, MAK 
decreased the expression of receptor-interacting protein kinase 3 mRNA and protein, a key molecule 
for necroptosis. These results suggest that MAK confers resistance to apoptotic and necroptotic cell 
death and relieves H/I-induced cerebral ischemic injury in type 2 diabetic mice. 
  3 
1. Introduction 
Type 2 diabetes, which is characterized by hyperglycemia associated with insulin resistance, is 
the most common metabolic disease in nearly all countries and is increasing explosively in 
developing countries [1]. The metabolic disorder of diabetes leads to characteristic complications 
contributing to the development of micro- and macrovascular atherosclerosis [2]. Patients with 
diabetes not only are predisposed to stroke but also often suffer exacerbated post-stroke damages 
[3-5]. In accordance with these clinical observations, basic studies have also demonstrated that the 
diabetic state aggravates cerebral ischemic injury in both type 1 [6-8] and type 2 diabetic animal 
models [9, 10]. The major causes exacerbating post-ischemic cerebral damage with diabetes are 
considered to be elevated levels of oxidative stress and inflammatory cytokines. Sustained 
hyperglycemia has been suggested to produce excessive intracellular reactive oxygen species (ROS) 
and enhance systemic oxidative stress, which accelerates apoptotic and proinflammatory processes 
in the brain tissue [11]. Furthermore, visceral obesity associated with type 2 diabetes also has been 
reported to induce production of inflammatory cytokines and augment oxidative stress via 
dysregulation of adipose tissue function [12, 13].  
Oxidative stress and subsequent inflammation are also involved in both the pathogenesis and 
development of cerebral ischemic injury [14, 15]. After ischemia, different types of cell death, i.e., 
necrosis and apoptosis, occur depending on the severity of hypoxia, ATP depletion, and the 
vulnerability of cells in the ischemic region [16]. Reperfusion after a long period of vessel occlusion 
triggers an explosive generation of ROS such as superoxide radical (O2−), hydroxyl radical, 
hydrogen peroxide, and nitrogen species [17]. Necrosis, an uncontrollable cell death, rapidly occurs 
mainly in the ischemic core region, and subsequently, apoptosis is induced in the ischemic 
penumbral region by oxidative damage to lipids, proteins, and DNA [15]. On the basis of these 
findings, neuroprotective therapy with free radical scavengers to remove ROS and rescue the cells in 
the ischemic penumbra is developing for the treatment of acute ischemic stroke coupled with 
thrombolytic therapy [18].  
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In nearly a decade, necroptosis as a novel type of programmed and controllable cell death with 
pathogenomic features similar to those of necrosis, has proved to contribute to various tissue 
pathological injuries, including neuronal cell death in cerebral ischemia [19, 20], neurodegeneration 
[21], and viral infections in the CNS [22], drawing interest toward necroptosis as a new target for 
therapy of these diseases. Necroptosis has been revealed to be triggered by the tumor necrosis factor 
(TNF) superfamily, such as TNF, Fas ligand, and TNF-related apoptosis inducing factor [23, 24]. 
TNF activates TNF receptor 1, recruiting a complex I comprising receptor-interacting protein kinase 
(RIP) 1 and other factors [25]. RIP1 deubiquitination dissociates the proteins of complex I from the 
receptor and induces transit of death-inducing signaling complex (DISC, complex II) consisting of 
RIP1, RIP3, procaspase-8 and Fas-associated death domain protein to the cytosol. During the 
inhibition of apoptosis, RIP1 and RIP3 form the necrosome by cross-phosphorylation, leading to 
necroptosis [25, 26]. Thus, the execution of necroptosis requires the kinase activity of 
receptor-interacting protein kinase RIP3 by a caspase-independent mechanism [27]. Recently, it has 
been shown that experimental ischemia increases the expression of RIP3 both in in vitro primary 
cultures of hippocampal neurons and in vivo rat hippocampal CA1, suggesting a contribution of 
RIP3 upregulation to the necroptotic process [28, 29]. There are a number of studies regarding the 
therapeutic approach for necroptotic cell death in cerebral ischemia [20, 21]; however, the 
explorations of these effective compounds have only recently begun. 
Many oriental herbal/traditional plant medicines with antioxidative activities have been 
demonstrated to prevent and cure lifestyle-related diseases, including type 2 diabetes and its 
complications, in humans and animals. Ganoderma lucidum (G. lucidum) is a very popular medicinal 
fungus used in traditional Chinese medicine; it has an extensive variety of pharmacological activities 
responsible for its health benefits such as antioxidant, anticancer, anti-inflammatory, and 
immunomodulatory activities [30]. The functional food derived from this fungus, a water-soluble 
extract from the culture medium of G. lucidum mycelia (MAK) is a freeze-dried powder of a 
hot-water extract prepared from a solid culture medium composed of bagasse and defatted rice bran 
overgrown with G. lucidum mycelia; this food has a considerable background of 18 years of 
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contributing to the health of consumers. Our previous reports revealed that chronic oral pretreatment 
with MAK relieves an exacerbation of cerebral injury induced by middle cerebral artery occlusion 
(MCAO) and reperfusion in streptozotoicin (STZ)-induced type 1 diabetic rats [31, 32]. MAK 
suppressed the augmentation of oxidative stress and expression of a number of proinflammatory 
genes or proteins, such as TNF-α, interleukin (IL)-1β, cyclooxiganase (COX)-2, and 
myeloperoxidase (MPO) in the STZ-induced diabetic rat brain, and decreased apoptotic cell death 
induced by MCAO/reperfusion in the ischemic penumbra [32]. These results imply that the 
cerebroprotective effects of MAK are mainly attributed to its antioxidant and anti-inflammatory 
properties. However, its efficacy in the ischemic injury of the type 2 diabetic animal model 
associated with obesity and insulin resistance has not been estimated. Therefore, in the present study, 
we investigated the protective effects of chronic oral pretreatment of MAK on cerebral ischemia 
injury induced by hypoxia/ischemia (H/I) in genetically obese diabetic KKAy mice, a model of 
human metabolic disorders. In this study, we demonstrate that chronic pretreatment with MAK 
prevents H/I-induced enhancement of the expression of RIP3 and decreases necrototic cell death as 
well as apoptosis in KKAy mice.  
 
2. Materials and Methods 
2.1. Preparation of MAK 
MAK was prepared by Noda Shokkin-Kogyo Co., Ltd. (Chiba, Japan), as previously described [33]. 
G. lucidum mycelia were cultured in a solid culture medium composed of bagasse and defatted rice 
bran for approximately 3–4 months just before the formation of the fruit body. The whole culture 
medium with a dense growth of the mycelia was extracted with hot water, subjected to filter 
sterilization, and thereafter freeze-dried to obtain MAK. 
 
2.2. Animals and treatments 
Male KK-Ay/TaJcl mice (7 week old) were purchased from CLEA Japan, Inc. (Tokyo, Japan). Each 
mouse was separately caged under the temperature-controlled environment (23 ± 0.5°C) and relative 
  6 
humidity (55% ± 10%) with a 12/12-h light–dark cycle. The mice were given a standard rodent 
chow (CE-2, CLEA Japan, Inc.) and water ad libitum. After acclimating for 1 week, the mice were 
divided into two groups; the MAK group, which were orally administered MAK (1 g/kg) dissolved 
in distilled water and the control group, which were administered only distilled water. A volume of 
0.05 mL/10 g body weight of the solutions was given via a stomach tube once daily during the next 
7 days. All experiments were performed in compliance with the Guiding Principles for the Care and 
Use of Laboratory Animals approved by the Japanese Pharmacological Society, and the guidelines 
were approved by the Ethics Committee on Animal Care and Animal Experimentation at the Josai 
University (number H23033). The number of animals used was kept to the minimum necessary for 
meaningful interpretation of the data. Animal discomfort was also minimized. 
 
2.3. Cerebral H/I 
At 9 weeks of age, KKAy mice were subjected to unilateral cerebral H/I (8% O2, balance N2, 20 min, 
36.0°C), as previously described [34]. Mice were anesthetized with 2% halothane and 30% O2 
balance air, a small incision was made in the neck, and the right carotid artery was isolated and 
double-ligated with a 4-0 surgical thread. After the incision was sutured, mice were allowed to 
recover mobility for access to food and water for 3 h. Then, the mice were exposed to systemic 
hypoxia for 20 min in a cylindrical glass chamber (10-cm diameter × 15.5-cm high) filled with 8% 
O2/balance N2, which was submerged in a 36.0°C water bath. The core body temperature of mice 
was maintained at 37.5–37.7°C. After the hypoxic exposure, mice were abruptly reoxygenated in the 
room air and returned to their cages with free access to food and water. The sham operation was 
given with the same manipulation without ligation of the right carotid artery and H/I to the 
control-sham and MAK-sham groups. All the mice were euthanized at 24 h after reoxygenation and 
the brain and plasma samples were collected. 
 
2.4. Systemic Oxidative Stress 
The serum levels of hydroperoxide as a marker of total oxidative stress were measured by an active 
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oxygen free radical autoanalyzer (Free Radical Elective Evaluator: F.R.E.E.) using the 
Diacron-Reactive Oxygen Metabolites (d-ROMs) test kit as previously reported [31-33, 35]. The 
results of the d-ROMs test were expressed in arbitrary units called “Carratelli units” (CARR U), 
where 1 CARR U corresponds to 0.08 mg/100 ml H2O2. F.R.E.E. and the kits were purchased from 
Diacron International s.r.l. (Grosseto, Italy). 
 
2.5. Rotarod performance test 
Impairments in motor coordination and balance in the mice were assessed by the accelerating 
rotarod test [36]. Mice were placed on a 3-cm diameter cylinder of the rotarod apparatus (MK-630B; 
Muromachi Kikai Co. Ltd., Tokyo, Japan) and accelerated from 4 to 40 rpm in 5 min. Trials began 
by placing the mouse on the rod and beginning the rotation. Each trial ended when the mouse fell off 
the rod and the latency was recorded. Mice were given five trials 2 days before H/I. Then the rotarod 
performance was tested for three trials 2 h before and 24 h after H/I.  
 
2.6. Neurological score 
Neurological evaluation was accomplished by a blinded observer before H/I and 24 h after H/I using 
the 18-point neurological scoring system [37]. This neurological score tests for spontaneous activity, 
motor impairments, and sensorial function. Severe impairments were graded 0 or 1 and no observed 
deficits were graded 3 (Table 1). 
 
2.7. Infarct size assessment [38, 8, 31, 32] 
At 24 h of reoxygenation, the mice were deeply anesthetized with halothane and decapitated. The 
brain was removed and cut into 2-mm coronal sections in a precooled mouse brain matrix. Slices 
were stained with 2% 2,3,5-triphenyltetrazolium chloride (TTC; Sigma-Aldrich, St. Louis, MO, 
U.S.A) at 37°C for 20 min and then fixed with 10% formaldehyde (Wako Pure Chemical Industries, 
Ltd., Osaka, Japan). Infarct areas were determined using an image analysis system (Scion Image 
1.62) and were integrated to obtain the infarct volumes per brain. Corrected infarct volume (%) = 
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[left hemisphere volume − (right hemisphere volume − the infarct volume)]/left hemisphere volume 
× 100. 
 
2.8. O2− production 
Intracellular O2− generation in the hippocampal CA1 and CA2 and the somatosensory area of the 
cortex region was detected by dihydroethidium (DHE) staining [39, 8]. Coronal brain sections (8-μm 
tick) were incubated with DHE (10 μmol/l, Sigma-Aldrich) in 10 mM phosphate-buffered saline (pH 
7.4) for 30 min at 37°C. After washing and mounting the sections in slide glasses, three microscopic 
fields at the CA1 and CA2 of each hemisphere were captured using a laser scanning confocal 
microscope (FluoView FV1000, OLYMPUS Co. Ltd., Tokyo, Japan). The fluorescence intensity of 
oxidized DHE in each field was quantified using an imaging software (FV10-ASW 1.7, 
OLYMPUS). 
 
2.9. Hematoxylin & eosin (H&E) staining [38] 
Mice were anesthetized and transcardially perfused with 0.9% NaCl followed by 4% 
paraformaldehyde (PFA). Mice brains were then removed and post-fixed for 24 h in PFA at 4°C. 
Isolated brains were embedded in paraffin wax, sectioned (3–4-μm thick), and stained with H&E, 
sequentially. The sections were evaluated by scanning the ischemic penumbral areas of the cerebral 
cortex and hippocampus containing the CA1 and CA2 regions under low-power magnification (40×) 
and then confirmed under higher power magnification (100×, 200×, and 400×). All histopathological 
scoring and evaluation was performed by blind evaluation without knowledge of the treatment. 
Images were obtained under a microscope (Olympus BX51; Olympus, Tokyo, Japan) equipped with 
a DP72 digital camera (Olympus). 
 
2.10. TUNEL staining 
Apoptosis in the brain tissues was evaluated by the TUNEL method with the “Apoptosis in situ 
Detection Kit Wako” (Wako Laboratories) [8, 32], which is based on the TUNEL (Terminal 
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deoxynucleotidyl Transferase (TdT)-mediated dUTP nick end labeling) procedure, i.e., the addition 
of fluorescein-dUTP to 3′-terminals of apoptotically fragmented DNA with TdT, followed by 
immunochemical detection using anti-fluorescein antibody conjugated with horseradish peroxidase 
(POD) and 3-3′-diaminobenzidine tetrachloride (DAB) as a substrate. The coronal brain slices (8-μm 
thick) were lightly counterstained with hematoxylin and observed under a microscope (BX51W1, 
OLYMPUS). Quantification of TUNEL positive cells was achieved by cell counting in the 
hippocampal CA1 and CA2 as well as the penumbral cortex region affected by H/I [32, 40]. Three 
randomly chosen visual fields were counted in each region by an investigator without the knowledge 
of the experimental conditions. The percentage of apoptotic cells was calculated by the apoptotic 
index as the number of positive-staining nuclei by the total number of nuclei. 
 
2.11. Immunohistochemistry [32, 8] 
The brain was perfused with cold saline and fixed with phosphate buffer (pH 7.4) containing 4% 
formaldehyde. Coronal brain sections (8-μm thick) were incubated with blocking buffer (4% w/v, 
Block Ace; Dainippon Sumitomo Pharma Co. Ltd., Osaka, Japan) for 2 h. Slides were incubated 
with polyclonal rabbit anti-cleaved caspase-3 or RIP3 antibody (1:100, Abcam, Cambridge, UK) in 
1% w/v Block Ace overnight at 4°C. After washing with PBS, these were correspondingly incubated 
with Cy3-conjugated secondary antibody (1:100, Chemicon, Temecula, CA, USA) for 2 h at room 
temperature. Finally, nuclei were stained with 4′, 6-diamidino-2-phenylindole (DAPI; Invitrogen, 
Carlsbad, CA, USA) for 15 min at room temperature, washed, and mounted using a mounting 
medium with 80% glycerol. Immunofluorescence was visualized using the fluorescence microscopy 
as described above. The percentage of cleaved caspase-3 positive cells was calculated as the number 
of the positive-staining nuclei to the total nuclei [32, 40]. Regarding RIP3, because a lower level of 
expression of this protein was observed in every cell hippocampus, the cells having an enhanced 
expression of RIP3 under a laser beam at constant intensity were determined as RIP3 positive. All 
histopathological scoring and evaluation was performed by blind evaluation without knowledge of 
the treatment. 
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2.12. Real-time PCR Analysis 
The temporal gene expression patterns of apoptotic markers (Bcl-2 and Bax) were evaluated by 
quantitative real-time RT-PCR analysis [41, 8, 32]. The total RNA from the ischemic penumbral 
cortex region at 6 or 24 h of reoxygenation was extracted with the RNeasy Micro Kit (QIAGEN, 
Hilden, Germany), according to the manufacturer’s instructions. Total RNA (0.5 μg) from each 
sample was reverse-transcribed with oligo dT and random hexamer primers using reverse 
transcriptase (PrimeScriptTM RT Enzyme Mix I, Takara RNA PCR Kit, Takara Biomedicals, Shiga, 
Japan). Real-time PCR was performed with 10 ng of cDNA and a pair of gene-specific primers 
(Takara Biomedicals) added to the SYBR Premix EX Taq (Takara Biomedicals) and subjected to 
PCR amplification in the iCycler iQ Real-Time Detection System (Bio-Rad Laboratories, Inc., 
Hercules, CA, USA). The expression of β-actin was used to normalize cDNA levels. 
 
2.13. Statistical Analysis 
Statistical differences between the various groups were assessed with a one-way analysis of variance 
(ANOVA) followed by post hoc Tukey’s multiple-comparison test. Comparisons within groups were 
performed with a paired t-test. Neurological deficit scores were analyzed by the Kruskal–Wallis test, 
followed by the Mann–Whitney U test. 
 
3. Results 
3.1. Physiological characteristic parameters 
KKAy mice showed moderate hyperglycemia and obesity typical in the type 2 diabetic model. 
Treatment with MAK (0.3 or 1 g/kg) for 1 week did not affect the body weight gain and blood 
glucose level of the mice (Table 2). 
 
3.2. Effects of MAK on H/I-induced infarction and neurological deficits 
The infarction found in the TTC-stained coronal brain sections from the representative mice of each 
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group at 24 h of reoxygenation after H/I is shown in Figure 1A. The intact area of the tissue is 
stained with deep red originating from the mitochondrial activity of living cells, whereas the infarct 
area is pale pink. There was no apparent damage in the brain of sham-operated animals. In the 
control group, the infarction area was extended to the ipsilateral corpus striatum and the cortex 
during 24 h of reoxygenation after H/I. The corrected infract volume of the control mice was 33.1 ± 
10.8% in KKAy, which was markedly increased compared with the value we obtained in the other 
experiment using nondiabetic C57BL/6J mice (1.8% ± 1.3%). The enlargement of cerebral infarction 
in KKAy was alleviated in the MAK groups and the values of infarct volume in 0.3 and 1 g/kg MAK 
groups decreased by 29.2% and 76.4% from that of the control group, respectively (Fig. 1B). In the 
rotarod test, H/I and subsequent reoxygenation significantly impaired motor coordination and 
balance in the control group, whereas the sham-operation itself caused no deficit (Fig. 1C). 
Pretreatment with MAK significantly and dose-dependently suppressed the deficits in locomotive 
function. In particular, the mice pretreated with 1 g/kg of MAK showed a markedly improved 
performance. In accordance with the results from the rotarod test, a severe neurological deficit in the 
control group was revealed by an 18-point neurological scoring system (Fig. 1D). In contrast, the 
MAK (1 g/kg) group showed a better neurological score compared with the control group.  
 
3.3. Effects of MAK on neuronal cell death in the ischemic penumbra 
H&E staining of the ischemic penumbral region of the cortex (Fig. 2A & B) and hippocampal CA1 
region (Fig. 2C & D) was performed to assess the H/I-induced tissue damage. In both the 
sham-operated control and MAK groups, H&E staining showed no abnormal neuronal cells in the 
cortex (Fig. 2A) and hippocampus CA1 region (Fig. 2C). On the other hand, marked cell atrophy 
and vacuolation of the parenchyma caused by H/I were observed in the ischemic cerebral cortex (Fig. 
2A). The nuclei of the neurons were visibly shrunken, often angular with hypereosinophilic 
cytoplasm (arrow). As shown in Figure 2C, H/I caused serious pathological alterations in the 
ischemic hippocampal CA1 region. Nuclei of many remaining neurons were shrunken with 
eosinophilic cytoplasm. These exhibited the hallmark features of necrotic neurons (arrow). Several 
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atrophic neurons produced nuclear fragments, conceivable apoptotic bodies (white arrow). Abundant 
vacuolation (arrow head), indicating degeneration and collapse of nerve fiber projections of neurons, 
emerged in the hippocampus. MAK was able to ameliorate the abovementioned pathological 
changes both in cerebral cortex and hippocampus (Fig. 2B & D). 
 
3.4. Effects of MAK on oxidative stress in plasma and brain 
To assess the effects of MAK on H/I-induced systemic oxidative stress, serum levels of 
hydroperoxide in the control and MAK groups were measured by the d-ROMs test at 24 h of 
reoxygenation after H/I (Fig. 3A). H/I and reoxygenation significantly increased this parameter in 
the control group, which was absent in the MAK group. 
Intracellular O2− generation induced by H/I in the penumbral cortex (Fig. 3B & C) and 
hippocampal CA1 region (Fig. 3D & E) was detected by histological staining with a fluorescent 
probe DHE. At 24 h of reoxygenation after H/I, O2– generation was remarkably augmented in 
neuronal cells in the control brain and significantly suppressed in the MAK-treated brain. There was 
no difference in the amount of O2− generation of the regions between control and MAK groups with 
sham operation.  
 
3.5. Effects of MAK on neuronal apoptosis 
TUNEL staining of the ischemic penumbral region of the cortex (Fig. 4A & B) and hippocampal 
CA1 region (Fig. 4C & D) was performed to determine nucleosomal DNA fragmentation 
accompanied by apoptotic cell death. In both the sham-operated control and the MAK groups, no 
TUNEL-positive cells were detected in the regions. The number of TUNEL-positive cells was 
increased in the control group by H/I and subsequent reoxygenation and remarkably suppressed by 
pretreatment with MAK. The activation level of caspase-3 which directly activates DNase in the 
apoptotic final process was determined by immunostaining for cleaved caspase-3, an activated form 
of this enzyme. Similar to the result of TUNEL staining, the number of cells expressing cleaved 
caspase-3 was remarkably increased by H/I and subsequent reoxygenation in the control group (Fig. 
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4E–H). Pretreatment with MAK significantly inhibited the caspase-3 activation induced by H/I and 
subsequent reoxygenation.  
 
3.6. Effects of MAK on gene expression of Bcl-2 and Bax 
The mRNA expression level of the apoptosis-related genes encoding Bcl-2 (Fig. 5A) and Bax (Fig. 
5B) in the penumbral cortex was quantified by real-time PCR. H/I and subsequent reoxygenation 
significantly decreased the expression level of Bcl-2 mRNA in the control group, whereas it did not 
change the level of Bcl-2 mRNA in the MAK group. On the other hand, the expression levels of Bax 
mRNA were not significantly different between groups. Therefore, the ratio of Bcl-2/Bax mRNA, 
which reflects a change in the balance between antiapoptosis and apoptosis-promoting genes, was 
significantly decreased in the control group compared with the sham-operated control group, 
whereas this ratio in the MAK group was almost equal to that of the sham-operated MAK group (Fig. 
5C). 
 
3.7. Effects of MAK on gene expression of RIP1 and RIP3 
The expression levels of RIP1 and RIP3 mRNA in the penumbral cortex for each group were 
quantified by real-time PCR. The expression of RIP1 mRNA showed no significant change by either 
H/I or MAK-treatment (Fig. 6A). On the other hand, H/I increased the expression level of RIP3 
mRNA, depending on the duration of reoxygenation (Fig. 6B). RIP3 mRNA upregulation was 
prevented by pretreatment with MAK.  
 
3.8. Effects of MAK on expression of RIP3 in the ischemic penumbra 
Figure 7 shows representative photographs of RIP3 immunostaining of the penumbral cortex and 
hippocampal CA1 region from each group. A lower level of the expression of RIP3 was observed in 
the cortex of control and MAK sham-operated groups. At 24 h of reoxygenation after H/I, the 
number of RIP3-positive cells that showed a markedly enhanced expression of RIP3 protein was 
increased both in the cortex (Fig. 7A & B) and CA1 (Fig. 7C & D) and significantly suppressed by 
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pretreatment with MAK.  
 
3.9. Effects of MAK on gene expression of TNF-α 
Because the process of necroptosis can be triggered by the TNF superfamily, we measured the 
expression levels of TNF-α mRNA in the penumbral cortex from each group (Fig. 8A). H/I 
markedly upregulated the gene expression of TNF-α in the control brain and upregulation was 
significantly suppressed by the pretreatment with MAK. The relative expression values of TNF-α 
mRNA were plotted versus those of RIP3 mRNA obtained from all individual penumbral cortices at 
6 (Fig. 8B) and 24 h (Fig. 8C) of reoxygenation, indicating a positive correlation between the 
expression values of TNF-α mRNA and those of RIP3 mRNA (correlation coefficient: 0.79 and 0.80 
for the data from 6 and 24 h after reoxygenation, respectively).   
 
4. Discussion 
In the present study, we demonstrated that 1-week oral pretreatment with MAK exerts moderate but 
significant protective effects against H/I-induced brain infarction and neurological deficits in type 2 
diabetic KKAy mice. MAK decreased the numbers of TUNEL- or cleaved caspase-3-positive cells in 
the penumbral cortex and hippocampus, suggesting that MAK can protect neuronal cells against 
H/I-induced apoptosis in type 2 diabetic mice. In addition, MAK markedly decreased necrotic cell 
atrophy and vacuolation, which was associated with a downregulated expression of RIP3, a key 
molecule of necroptosis, in the ischemic penumbra. These results suggest that chronic pretreatment 
with MAK exerts significant antiapoptotic and antinecroptotic effects in the ischemic brain of the 
type 2 diabetic mice.  
MAK has been used as a revitalizer for 18 years, and a number of studies have demonstrated its 
antitumor [42] and immunomodulating activities [43]. However, the mechanistic basis and active 
ingredients responsible for its pharmacological effects have not been well defined. MAK is 
composed of bagasse and defatted rice bran that is overgrown with G. lucidum mycelia, which are 
considered to contain various bioactive substances, including triterpenes, polysaccharides, 
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water-soluble lignin, and its degradation products such as syringic acid and vanilic acid. Our group 
has revealed that MAK exerts antioxidative activities in vitro [44] and in vivo [31-33, 44]. MAK 
shows antidiabetic effects by relieving oxidative stress in STZ-induced type 1 diabetic animals; 
MAK ameliorates lipid peroxidation and dysfunction of antioxidative enzymes (superoxide 
dismutase, catalase and glutathione peroxidase) in the brain [31], liver, and kidney [44] in diabetic 
animals. Furthermore, MAK prevents MCAO/reperfusion-induced apoptosis and inflammatory 
responses in neuronal cells and reduces the size of cerebral infarction [31, 32]. The safety of MAK 
has been confirmed by in vitro toxicological evaluation and animal toxicity studies, and there has 
been no report suggesting that MAK had potential acute or long-term toxicities in consumers in the 
past, supporting the assertion that 1 week treatment with 1 g/kg MAK used in the present study has 
little or no toxicity.  
Previous basic studies have demonstrated that both type 1 [6–8] and type 2 diabetes [9, 10] 
augment oxidative stress and aggravate ischemic injury in the brain. The augmentation of the 
intracellular glucose oxidation process and nonenzymatic glycation of protein molecules enhanced 
by diabetic hyperglycemia is considered to lead to the overproduction of ROS and oxidative damage 
of neurons, triggering the apoptotic process in the cells [7, 11, 45]. Apoptotic cell death in the 
ischemic penumbra has been demonstrably enhanced by diabetes and correlated with serum glucose 
[6]. Our current study showed that oral pretreatment with MAK suppressed H/I-induced 
enhancement of systemic oxidative stress, O2− generation, and apoptotic cell death in the ischemic 
penumbra of KKAy mice, which could be attributed to the improved antioxidant status and reduced 
oxidative stress in the diabetic state. We observed that MAK decreased H/I-induced neuronal cell 
death in KKAy mice without any significant effects on body weight gain or blood glucose, 
confirming that the cerebroprotective effects of MAK could be due to its antioxidant activity.  
Mitochondria play an essential role in cerebral ischemia with diabetes [46]. Hyperglycemia has 
been suggested to impair mitochondrial functions and induce excess ROS production, leading 
neuronal cells to apoptosis. Mitochondrial-formed oxidants are mediators of molecular signaling in 
the mitochondria-dependent intrinsic apoptosis pathway involving cytochrome c release from the 
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mitochondria into the cytosol as a crucial process [47]. In this pathway, a proapoptotic factor Bax 
protein increases the permeability of the mitochondrial membrane by translocation from the 
cytoplasm to the membrane and initiates cytochrome c release; Bcl-2 is an antiapoptotic protein 
which counteracts Bax, binding to the outer mitochondrial membrane, maintaining membrane 
integrity, and enhancing cell survival [48, 49]. Therefore, the Bcl-2/Bax ratio can be taken as an 
index responsible for the execution of mitochondria-dependent apoptosis. In our study, the 
Bcl-2/Bax mRNA ratio was increased by H/I, suggesting that H/I caused mitochondrial dysfunction 
by mitochondrial-generated ROS accumulation in the cells. Pretreatment with MAK increased the 
levels of antiapoptotic Bcl-2 mRNA and the Bcl-2/Bax mRNA ratio. MAK also markedly decreased 
the number of cells overexpressing activated caspase-3, the executioner of apoptosis in the ischemic 
penumbral regions [48]. In addition, we showed that MAK prevented the H/I-induced increase in 
TNF-α mRNA expression in the penumbral cortex. The extrinsic pathway of apoptosis, triggered by 
the activation of the TNF superfamily cell-death receptors, which recruits other proteins to form a 
complex that ultimately activates caspase-3, has been clarified [50]. Overall, our present results 
suggest that MAK inhibits apoptotic cell death in the ischemic penumbra by concomitant inhibition 
of intrinsic and extrinsic pathways of apoptosis, presumably via an increase in the Bcl-2/Bax ratio 
and suppression of the expression of TNF-α. 
In the exacerbation mechanisms of post-stroke brain damage with diabetes, a magnified 
inflammation and associated uncontrolled necrotic cell death are critically involved [15]. H&E 
staining revealed that MAK markedly decreased necrotic cell death, induced by H/I and 
reoxygenation, in the penumbral cortex and hippocampus. Necrotic cell death facilitates 
inflammatory responses during the acute period after ischemia because necrotic cells rapidly lose 
plasma membrane, which leads to the release of immunostimulatory adjuvants such as high-mobility 
group box protein 1 from the cells, triggering inflammation storm [51]. This necrosis was considered 
to occur incidentally and to be uncontrolable, until necroptosis, a novel type of programmed and 
controllable necrosis extrinsically triggered by the TNF superfamily, became recognized [19]. For 
the execution of necroptosis, the kinase activity of RIP3 is required [26, 27]. Several groups have 
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demonstrated that the ischemic condition upregulates the expression of RIP3 in neurons [28, 21]. 
Vieira et al. [28] have shown that RIP3 knock-down suppresses the oxygen-glucose 
deprivation-induced necroptosis whereas RIP3 overexpression enhances the cell death in 
hippocampal culture neurons, suggesting an involvement of regulation of the expression of RIP3 in 
necroptosis pathway. Therefore, we investigated the effects of MAK on the expression of RIP3 in 
the ischemic penumbral regions. Immunohistochemistry revealed that H/I and subsequent 
reoxygenation upregulated the expression of RIP3 in both the cortex and hippocampus. This was 
compatible with the data showing an upregulation in gene expression of RIP3. We observed that 
pretreatment with MAK prevented the H/I-induced RIP3 mRNA and protein upregulation in the 
ischemic penumbra. Furthermore, we found that the gene expression levels of TNF-α and RIP3 were 
positively correlated, suggesting that TNF-α could positively regulate RIP3 transcription. MAK may 
alleviate the H/I-induced RIP3 upregulation via a TNF-α downregulation in the neuronal cells of the 
ischemic penumbra. Accumulated adipose tissue-induced dysregulated production of adipocytokines 
occurring in visceral obesity associated with type 2 diabetes has been reported to induce the 
production of proinflammatory cytokines, including TNF-α, and augment oxidative stress via the 
dysregulation of adipose tissue function [12, 13]. Previously, we indicated that pretreatment with 
MAK suppresses focal cerebral ischemia-induced activation of nuclear factor (NF)-κB, a 
transcription factor responsible for inflammation leading to abundant TNF production in microglia, 
and decreased expression of TNF-α, IL-1β, COX-2, and MPO in the cells of the type 1 diabetic rat 
brain [32]. Recently, a study has shown that G. lucidum fungus mixture obtained by nearly the same 
preparation method as that of MAK suppresses the expression of TNF-α in the hippocampus after 
MCAO/reperfusion in rats [52], which is consistent with our findings. Other studies have reported 
that polysaccharides [53] and triterpenes [54] extracted from the G. lucidum fruit body suppress 
lipopolysaccharide-induced expression of inflammatory mediators via an inhibition of NF-κB 
activity. Therefore, one possibility is that MAK inhibits inflammatory responses via inhibition of 
monocyte activation. Further experiments are needed to elucidate more detailed neuroprotective 
mechanisms of MAK and identify its active ingredients. 
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5. Conclusions 
In conclusion, chronic treatment with MAK prevents necrototic cell death as well as apoptosis 
induced by H/I in KKAy mice brain, which may be attributed to its antioxidant and 
anti-inflammatory activities. MAK downregulates TNF-α in the ischemic penumbra, which may 
abrogate RIP3 upregulation and prevent the neuronal necroptosis.   
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Figure legends 
Fig. 1 Effects of chronic pretreatment with MAK on H/I-induced infarction and neurological 
deficits  
(A) Representative data of triphenyltetrazolium chloride (TTC) staining from the coronal brain 
sections at 24 h of reoxygenation after H/I in the mice. Scale bar = 1 mm. (B) The infarction volume 
was determined using an image analysis system. Throughout, the data are represented as means ± 
S.D.; n = 6–10 in each group. ***P < 0.001 compared with the sham-operated control group, ††, †††P 
< 0.01, 0.001. (C) Motor coordination and balance at 24 h of reoxygenation after H/I was assessed 
by the rotarod performance test in the mice. *, ***P < 0.05, 0.001 compared with the respective 
sham-operated groups. †††P < 0.001 compared with the H/I-treated control group. (D) Neurological 
deficits were assessed using the 18-point neurological scoring system consisting of the neurological 
scoring index (Table 1) at 24 h of reoxygenation after H/I in the mice. The score for each mouse was 
summed for all five individual test scores. The maximum neurological score of a normal mouse with 
no deficit is 18. ***P < 0.001 compared with the respective sham-operated groups. †††P < 0.001 
compared with the H/I-treated control group. 
 
Fig. 2 Effects of chronic pretreatment with MAK on neuronal cell death in the ischemic 
penumbra 
Representative photographs obtained by H&E staining from the coronal brain sections, including the 
ischemic penumbral cortex (A) and hippocampus CA1 region (C) at 24 h of reoxygenation after H/I 
in the mice.; arrow: necrotic neuron with shrunken, often angular nucleus with hypereosinophilic 
cytoplasm, white arrow: apoptotic neuron with fragmented nucleus, arrow head: vacuolation. The 
severity of the histopathological findings (upper panels: necrotic cell death, lower panels: 
vacuolation of the regions) in the ischemic penumbral cortex (B) and hippocampus CA1 region (D) 
were scored as (0) normal, (1) minimal, (2) mild, (3) moderate, and (4) marked; n = 4–5 in each 
group. 
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Fig. 3 Effects of chronic pretreatment with MAK on systemic and cerebral oxidative stress 
after H/I 
(A) The levels of total plasma oxidative stress before H/I and at 24 h of reoxygenation in each group 
were determined by the d-ROMs test.; n = 6–10 in each group. **P < 0.01 compared with the 
control group before H/I, †P < 0.05 compared with the control group after H/I. Representative data 
of DHE staining for superoxide production at 24 h of reoxygenation after H/I in the penumbral 
cortex (B) and hippocampal CA1 region (D) from the mice in each group. Scale bar = 50 μm. 
Fluorescence intensity of the oxidized DHE was quantified using imaging software in the penumbral 
cortex (C) and hippocampal CA1 region (E). The values of fluorescence intensity of each group are 
represented as means ± S.D. relative to those of the cortex in the control group; n = 3–5. **, ***P < 
0.01, 0.001 compared with the sham-operated control group, †P < 0.05 compared with the 
H/I-treated control group.  
 
Fig. 4 Effects of chronic pretreatment with MAK on apoptotic cell death in the ischemic 
penumbral regions 
Representative photographs of TUNEL staining and cleaved caspase-3 immunostaining at 24 h of 
reoxygenation after H/I in the penumbral cortex (A), (E) and hippocampal CA1 region (C), (G) from 
the mice in each group. Scale bar = 50 μm. Quantification of the number of TUNEL-positive (arrow 
heads) or cleaved caspase-3 positive cells was achieved by cell counting in the penumbral cortex (B), 
(F) and hippocampal CA1 region (D), (H). Throughout, data are represented as means ± S.D. n = 
3–5. ***P < 0.001 compared with the respective sham-operated groups. †, ††P < 0.05, 0.01 compared 
with the H/I-treated control group. 
 
Fig. 5 Effects of chronic pretreatment with MAK on expression of apoptosis factors gene 
expression after H/I 
Expression levels of Bcl-2 (A) and Bax (B) mRNA after H/I at 24 h of reoxygenation after H/I in the 
penumbral cortex from the mice in each group, determined by real-time RT-PCR analysis. (C) The 
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Bcl-2/Bax ratio was calculated.; n = 6–7 in each group. *, ***P < 0.05, 0.001 compared with the 
sham-operated control group, †, †† P < 0.05, 0.01 compared with the H/I-treated control group. 
 
Fig. 6 Effects of chronic pretreatment with MAK on the expression of necroptotic factor gene 
expression after H/I 
Expression levels of RIP1 (A) and RIP3 (B) mRNA at 6 (Post 6 h) or 24 h (Post 24 h) of 
reoxygenation after H/I in the penumbral cortex from the mice in each group, determined by 
real-time RT-PCR analysis.; n = 6–10 in each group. **, ***P < 0.01, 0.001. ††P < 0.01 compared 
with the H/I-treated control group. 
 
 
Fig. 7 Effects of chronic pretreatment with MAK on RIP3 expression in the ischemic 
penumbral regions 
(A) Representative photographs of RIP3 immunostaining at 24 h of reoxygenation after H/I in the 
penumbral cortex (A) and hippocampal CA1 region (C) from the mice in each group. Scale bar = 50 
μm. Quantification of the number of RIP3 positive cells was achieved by cell counting in the 
penumbral cortex (B) and hippocampal CA1 region (D) from the mice in each group. Throughout, 
data are represented as means ± S.D. from 3–5 mice in each group. ***P < 0.001 compared with the 
respective sham-operated groups. † P < 0.05 compared with the H/I-treated control group. 
 
Fig. 8 Effects of chronic pretreatment with MAK on expression of TNF-α gene expression after 
H/I 
(A) Expression levels of TNF-α mRNA at 6 (Post 6 h) or 24 h (Post 24 h) of reoxygenation after H/I 
in the penumbral cortex from the mice in each group, determined by real-time RT-PCR analysis; n = 
6–7 in each group. *, **, ***P < 0.05, 0.01, 0.001 compared with the respective sham-operated 
groups. †† P < 0.01 compared with the H/I-treated control group. The relative expression values of 
TNF-α mRNA was plotted versus those of RIP3 mRNA obtained from all individual penumbral 
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cortices at 6 (B) and 24 h (C) of reoxygenation after H/I. The data were pooled from the control 
(open circles) and MAK-pretreated (closed circles) mice. 
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Table 1. Neurological Scoring Index [37] 
 Scores 
 0 1 2 3 
Spontaneous activity, 
3 min No movement Slight movement 
Touches 1-2 
sides of the 
cage 
Touches 3-4 sides of 
the cage 
Symmetry of 
movement, right 
forelimb and hind 
limb 
Total 
asymmetry 
Near-total 
asymmetry 
Mild 
asymmetry Complete symmetry 
Floor walking No walking Walks only in circles 
Curvilinear 
path Straight path 
Beam walking Falls off the beam Hugs the beam 
Stands on the 
beam Walks on the beam 
Response to vibrissae 
touch  No response 
Weak 
response 
Symmetrical response 
as compared to 
unaffected side 
Side stroking  No response Weak response 
Symmetrical response 
as compared to 
unaffected side 
 
 
Table 2. Body weight, feed intake, and blood glucose in mice during MAK treatment 
Group 
Body weight (g) 
 
Feed intake (g) 
 
Blood glucose (mg/dL) 
Day 0 Day 7   Day 0 Day 7   Day 0 Day 7 
Control (H2O) 37.2 ± 1.3 38.4 ± 1.5   6.0 ± 0.8 6.3 ± 0.6   350 ± 119 383 ±103 
MAK 0.3 g/kg 37.6 ± 1.3 37.5 ± 1.9 
 
6.1 ± 0.6 6.3 ± 0.6 
 
375 ± 193 358 ± 133 
MAK 1 g /kg 37.1 ± 1.1 37.7 ± 1.1   6.3 ± 0.6 6.2 ± 0.6   352 ± 116 346 ± 97 
 
Results are the mean ± S.E.M. The number of mice per group was: control group, n = 10; MAK (0.3 
g/kg)-treated group, n = 6; MAK (1 g/kg)-treated group, n = 9. 
 
  
Fig. 1 
*** P < 0.001 vs. the respective sham groups. 
††† P < 0.001 vs. Control-H/I. n=6-10. 
  
*, *** P < 0.05, 0.001 vs. the respective sham groups. 
††† P < 0.001 vs. Control-H/I. n=6-10. 
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